Oxford Immunotec Partners with Valneva on Phase 1/2 COVID-19 Vaccine Trial

Oxford Immunotec is teaming up with Valneva to help the French biotech with a phase 1/2 UK trial of its inactivated COVID-19 vaccine candidate, VLA2001.

Specifically, Oxford Immunotec will conduct testing on vaccinated trial participants using its T- cell response diagnostic to determine if the vaccination generates a T-cell response in patients.

Valneva’s phase 1/2 study, which began in December, is assessing the safety and immunogenicity of three dosage levels (low, medium and high) of a two-dose regimen in approximately 150 healthy adults.

The company said it expects to report initial safety and immunogenicity data in April and plans to ultimately test its vaccine in more than 4,000 patients in additional trials.